重组人生长激素联合芳香化酶抑制剂治疗特发性矮小症的效果及安全性(1)
【摘要】 目的：对特发性矮小症患儿应用重组人生长激素(rhGH)联合芳香化酶抑制剂治疗的临床效果进行探究。方法：选取2015年5月-2016年7月于笔者所在医院接受治疗的56例特发性矮小症患儿，均为男性，随机分成对照组(采用rhGH治疗)与研究组(采用rhGH联合芳香化酶抑制剂治疗)，每组28例。比较两组治疗前后生长速度、预测身高、骨龄及治疗过程中不良反应情况。结果：治疗前两组生长速度、预测身高、骨龄比较，差异均无统计学意义(P>0.05);治疗后研究组生长速度、预测身高、骨龄均优于对照组，差异均有统计学意义(P<0.05);治疗期间，两组不良反应发生率比较，差异无统计学意义(P>0.05)。结论：对特发性矮小症患儿采用rhGH联合芳香化酶抑制剂治疗，可有效改善生长速度、身高及骨龄情况，且未增加不良反应，安全性较高，值得推广。
【关键词】 重组人生长激素 芳香化酶抑制剂 特发性矮小症 不良反应
doi：10.14033/j.cnki.cfmr.2020.08.013 文献标识码 B 文章编号 1674-6805(2020)08-00-03
Efficacy and Safety of Recombinant Human Growth Hormone Combined with Aromatase Inhibitor in the Treatment of Idiopathic Dwarfism/WANG Hui， ZHUANG Zhaoming. //Chinese and Foreign Medical Research， 2020， 18(8)： -34
[Abstract] Objective： To explore the clinical effect of Recombinant Human Growth Hormone (rhGH) combined with aromatase inhibitor in the treatment of idiopathic dwarfism. Method： A total of 56 male children with idiopathic dwarfism who came to our hospital from May 2015 to July 2016 were selected and randomly divided into the control group (rhGH treatment) and the study group (rhGH combined with aromatase inhibitor treatment)， 28 cases in each group. The growth rate， predicted height， bone age before and after treatment and adverse reactions during treatment of the two groups were compared. Result： Before treatment， the growth rate， predicted height， bone age were compared between the two groups， and the differences were not statistically significant (P>0.05). After treatment， the growth rate， predicted height， bone age of the study group were better than those of the control group， and the differences were statistically significant (P<0.05). During treatment， the incidence of adverse reactions was compared between the two groups， and the difference was not statistically significant (P>0.05). Conclusion： In the treatment of idiopathic dwarfism， rhGH combined with aromatase inhibitor can help children improve the growth rate， height and bone age. Meanwhile， the adverse reactions are not increased. It is safe and worthy of promotion.
[Key words] Recombinant Human Growth hormone Aromatase inhibitor Idiopathic dwarfism Adverse reactions
First-author’s address： Xiamen Children’s Hospital， Xiamen 361000， China
目前，特發性矮小症的发病机制尚不明确。因此，针对特发性矮小症患者尚无特异性治疗方法[1]。在特发性矮小症治疗中，临床医师普遍采用重组人生长激素(rhGH)、促性腺激素释放激素(GnRHa)、芳草化酶抑制剂等，治疗效果各不相同[2-3]。鉴于此，本次以56例特发性矮小症患儿作为研究对象，探究芳香化酶抑制剂联合rhGH的效果，报道如下。, http://www.100md.com(王慧 庄昭明)
【关键词】 重组人生长激素 芳香化酶抑制剂 特发性矮小症 不良反应
doi：10.14033/j.cnki.cfmr.2020.08.013 文献标识码 B 文章编号 1674-6805(2020)08-00-03
Efficacy and Safety of Recombinant Human Growth Hormone Combined with Aromatase Inhibitor in the Treatment of Idiopathic Dwarfism/WANG Hui， ZHUANG Zhaoming. //Chinese and Foreign Medical Research， 2020， 18(8)： -34
[Abstract] Objective： To explore the clinical effect of Recombinant Human Growth Hormone (rhGH) combined with aromatase inhibitor in the treatment of idiopathic dwarfism. Method： A total of 56 male children with idiopathic dwarfism who came to our hospital from May 2015 to July 2016 were selected and randomly divided into the control group (rhGH treatment) and the study group (rhGH combined with aromatase inhibitor treatment)， 28 cases in each group. The growth rate， predicted height， bone age before and after treatment and adverse reactions during treatment of the two groups were compared. Result： Before treatment， the growth rate， predicted height， bone age were compared between the two groups， and the differences were not statistically significant (P>0.05). After treatment， the growth rate， predicted height， bone age of the study group were better than those of the control group， and the differences were statistically significant (P<0.05). During treatment， the incidence of adverse reactions was compared between the two groups， and the difference was not statistically significant (P>0.05). Conclusion： In the treatment of idiopathic dwarfism， rhGH combined with aromatase inhibitor can help children improve the growth rate， height and bone age. Meanwhile， the adverse reactions are not increased. It is safe and worthy of promotion.
[Key words] Recombinant Human Growth hormone Aromatase inhibitor Idiopathic dwarfism Adverse reactions
First-author’s address： Xiamen Children’s Hospital， Xiamen 361000， China
目前，特發性矮小症的发病机制尚不明确。因此，针对特发性矮小症患者尚无特异性治疗方法[1]。在特发性矮小症治疗中，临床医师普遍采用重组人生长激素(rhGH)、促性腺激素释放激素(GnRHa)、芳草化酶抑制剂等，治疗效果各不相同[2-3]。鉴于此，本次以56例特发性矮小症患儿作为研究对象，探究芳香化酶抑制剂联合rhGH的效果，报道如下。, http://www.100md.com(王慧 庄昭明)